Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Clin Cancer Res. 2010 Jun 22;16(13):3399–3408. doi: 10.1158/1078-0432.CCR-09-3087

Figure 4.

Figure 4

Effect of tumor rechallenge on CD8 and NK cell activation. Normal mice and CpG-ODN-treated mice (4 injections) that had survived for at least three months after initial tumor inoculation were rechallenged with an intracranial injection of GL261 cells. Brain and blood samples from normal (naïve) (N), GL261-challenged naïve (T), CpG-ODN-treated survived (CS), and GL261-rechallenged CpG-ODN-treated survived mice (CR) were harvested and compared by flow cytometry for (A) IFNγ production, (B) activation of CD8 and NK cells (CD107a expression), and (C) CD8 and NK cytotoxicity activity against GL261 target cells. ns: not significant, *: p<0.05; **: p<0.001. n=4 mice for each treatment group. Data is representative of two separate experiments.